ULCERATIVE COLITIS

This study follows 120 people with ulcerative colitis in Sweden who are already prescribed tofacitinib as part of their normal care. Researchers will use a national registry to see how many achieve remission and stick with the treatment. The goal is to understand how well the dru…

This early study tests if a nerve stimulation device can safely help people with moderate to severe ulcerative colitis that hasn't improved with standard treatments. Fifteen adults will receive the implant and be followed for a year to see if their symptoms get better. The goal i…

This study tests whether a diet made of common American foods like grilled meats, sandwiches, and oatmeal can reduce inflammation and help people with ulcerative colitis feel better. Researchers will track symptoms and measure a marker of gut inflammation. The study enrolls 122 a…

This program provides early access to upadacitinib, an investigational drug, for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis. It is only available to those who have no other suitable treatment options and cannot join a clinica…

This study tests whether taking prebiotics for 8 weeks can improve gut health in people with ulcerative colitis or Crohn's disease. Researchers will track symptoms and analyze stool samples to see if prebiotics change the gut microbiome and reduce inflammation. 70 adults with act…

This study tests an oral drug called etrasimod in 36 adolescents (ages 12 to under 18) with moderate to severe ulcerative colitis, a chronic bowel disease. The goal is to see if the drug can safely reduce inflammation and help patients feel better over 52 weeks, with an option to…

This study tests a new drug called ISM5411 in 80 adults with active ulcerative colitis, a condition causing inflammation in the colon. Participants will receive either the drug or a placebo to see if it is safe and helps control symptoms. The goal is to manage the disease, not cu…

This study looks at how well the drug risankizumab works for adults with moderate to severe ulcerative colitis in real-world clinics across Japan. About 200 people who are already prescribed the drug by their doctor will be followed for up to 3 years. The goal is to see if the dr…

This study looks at the long-term safety of a drug called vedolizumab in children and teenagers with ulcerative colitis or Crohn's disease. About 70 participants who responded well to the drug in an earlier study will continue treatment, while others who did not respond well will…

This study tests whether giving several fecal microbiota transplants (FMT) works better than just one to clear recurrent C. difficile infection in people with ulcerative colitis. About 64 adults with active colitis and repeat C. diff will be randomly assigned to receive either a …

This study tests whether adding a new drug (LY4268989) to an existing one (mirikizumab) works better than mirikizumab alone for adults with moderate-to-severe ulcerative colitis. About 252 participants will receive treatment for up to 104 weeks. The goal is to see if the combinat…

This study tests a drug called risankizumab in children aged 2 to 18 with moderate to severe ulcerative colitis, a condition causing colon inflammation and bleeding. The trial will check how the drug works in the body, its safety, and its ability to reduce symptoms. Around 120 ch…

This study looks at how well and how safely the drug mirikizumab works over a long period (about 3 years) in children and teenagers with moderate-to-severe ulcerative colitis or Crohn's disease. About 150 participants who have already been in earlier studies will continue treatme…

This study tests an experimental drug called MK-8690 for people with moderate to severe ulcerative colitis, a chronic gut condition causing inflammation and symptoms like diarrhea and bleeding. About 100 adults will receive either the drug or a placebo to see if it can bring abou…

This study looks at how well risankizumab works for adults with moderate to severe ulcerative colitis in everyday medical practice. About 200 participants in Germany and Austria will receive the drug as prescribed by their doctor and be followed for up to 52 weeks. The main goal …

This study tests a subcutaneous (under the skin) version of vedolizumab in 70 children with moderate to severe ulcerative colitis or Crohn's disease who already responded to the IV form. The goal is to see how the body handles the drug and if it is safe. Participants receive the …

This study looks at whether a weight loss procedure called Endoscopic Sleeve Gastroplasty (ESG) is safe and effective for people with ulcerative colitis who are obese and need colon removal surgery. About 12 participants will be enrolled. The goal is to help them lose weight befo…

This program provides children and teenagers with moderate to severe ulcerative colitis or Crohn's disease continued access to vedolizumab, a medication given through an IV. It is for those who completed a prior study and still benefit from the treatment, with no good alternative…

This study tests a daily pill called filgotinib in about 80 children and teens (ages 8 to 17) with moderate to severe ulcerative colitis. The goal is to see if the drug can reduce symptoms and help the bowel heal, while checking for side effects. Participants take the medicine at…

This study tests a steroid tablet (budesonide) in 70 children aged 5-17 with mild to moderate ulcerative colitis. The goal is to see if the drug can safely bring the disease into remission (no symptoms) within 56 days. Participants may continue their usual medications. This is a …

This study looks at whether removing certain food additives (like carrageenan and polysorbates) from the diet can help people with mild-to-moderate ulcerative colitis. 70 participants will either eat a normal healthy diet or one that avoids these additives for one month. Research…

This study tests whether adding a freeze-dried fecal transplant (LFMT) to standard biologic therapy (vedolizumab or ustekinumab) is safe and helps more people with ulcerative colitis reach remission. About 40 adults with active UC will receive either LFMT or a placebo alongside t…

This study tests whether taking frozen capsules containing healthy donor stool (or filtered stool) can help control mild to moderate ulcerative colitis. About 129 adults who have not responded to standard treatments will receive either the stool capsules or a placebo. The main go…

This study tests whether breathing pure oxygen in a pressurized chamber (hyperbaric oxygen therapy) can help people hospitalized with moderate to severe ulcerative colitis feel better faster. Researchers want to see if this treatment can reduce the need for stronger medications o…

This study tests two drugs, eltrekibart and mirikizumab, given alone or together, in 140 adults with moderate-to-severe ulcerative colitis. The goal is to see if they can safely reduce symptoms and help the gut heal. Participants must have tried other treatments without success.

This study looks at how well the drug upadacitinib (RINVOQ) controls symptoms of ulcerative colitis, a condition that causes inflammation and bleeding in the colon. About 400 adults in Germany, Austria, and Switzerland who are already prescribed the drug will be followed for up t…

This study explores whether fecal transplants (capsules containing healthy donor stool) can improve quality of life and control inflammation in people newly diagnosed with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, or ulcerative colitis. T…

This study looks at whether vedolizumab can help people with moderate to severe ulcerative colitis or Crohn's disease achieve remission (no symptoms) after 14 weeks of treatment. About 400 adults aged 18 to 80 will receive vedolizumab first as an IV infusion, then as a shot under…

This study tests if rupatadine, an allergy medicine, can help control inflammation and symptoms in people with mild-to-moderate ulcerative colitis. About 60 adults will take the drug and be monitored for safety and effectiveness. The goal is to manage the disease, not cure it.

This study looks at the long-term safety of the drug vedolizumab in children with ulcerative colitis or Crohn's disease. It is for kids who already completed a previous vedolizumab study. Researchers will track side effects and major bowel-related events over time.

This study compares two approved drugs, risankizumab and vedolizumab, to see which works better for adults with moderate to severe ulcerative colitis who haven't tried targeted therapies before. About 530 participants will receive one of the two medications, and researchers will …

This study is for people who have both an autoimmune disorder (like rheumatoid arthritis, lupus, or multiple sclerosis) and advanced cancer that has spread or cannot be removed. It tests a drug called nivolumab, which helps the immune system fight cancer, given alone or with othe…

This study tests a new medicine called duvakitug for people with moderate to severe ulcerative colitis. Participants who already responded to duvakitug in an earlier study will continue treatment for up to 5 years to see if it safely maintains remission. The goal is to control th…

This study is testing whether transplanting healthy stool bacteria into people with ulcerative colitis can help control the disease. It involves 85 adults with active colitis who will receive either the transplant or a placebo. The goal is to see if this approach is worth testing…

This study tests a drug called mirikizumab in children aged 2 to 17 with moderate to severe ulcerative colitis, a chronic bowel disease. The goal is to see if the drug can help control the disease and improve symptoms over 52 weeks. About 60 children who have not responded to oth…

This study looks at the long-term safety of an oral medication called zasocitinib (TAK-279) for people with moderate to severe Crohn's disease or ulcerative colitis. Participants who responded to the drug in earlier studies can continue treatment for up to 2 years. The main goal …

This study tests whether a combination of two drugs, vedolizumab and tofacitinib, can help adults with moderate to severe ulcerative colitis achieve remission. Participants receive both drugs for 8 weeks, then those who respond continue with vedolizumab alone for 44 weeks. The go…

This study tests whether adding tirzepatide (a weight-loss drug) to mirikizumab (an anti-inflammatory drug) helps people with moderate-to-severe ulcerative colitis who are also overweight or obese. About 350 adults will receive either both drugs or mirikizumab alone for up to 52 …

This study tests a new oral drug called BRS201 in 20 adults with severe ulcerative colitis who have not improved with standard treatments. Participants take the drug twice daily for 4 weeks and attend 8 clinic visits for blood, stool, and urine tests. The goal is to see if BRS201…

This study tests a new medicine, duvakitug, to see if it can help people with moderate to severe ulcerative colitis feel better and reach remission. About 980 adults will receive either the drug or a placebo for up to 12 weeks. The goal is to reduce bowel urgency, bleeding, and i…

This early-stage study is testing a probiotic pill called R-3750 in 36 adults with mild to moderate ulcerative colitis. The main goal is to see if the pill is safe and tolerable. Participants will take the probiotic by mouth and report their symptoms, while researchers check bloo…

This study tests a new drug, RO7837195, for people with moderate-to-severe ulcerative colitis who haven't gotten better with other treatments. About 224 participants will receive either the drug or a placebo to see if it can bring the disease under control. The main goal is to ac…

This study tests a remote monitoring app (MedicWise) for people with active Crohn's disease or ulcerative colitis. About 290 adults will use the app to track symptoms and health data, with the goal of spending more time in remission over 12 months. The app automatically collects …

This study tests an experimental drug called tilpisertib fosmecarbil (GS-5290) in 176 adults with moderate to severe ulcerative colitis. Participants will receive either the drug or a placebo for 12 weeks to see if it helps reduce symptoms like diarrhea, bleeding, and inflammatio…

This study tests whether long-acting antibodies, given alone or together, can safely reduce inflammation and improve symptoms in adults with moderate-to-severe ulcerative colitis. About 645 participants will receive the treatment through an IV infusion followed by regular shots. …

This study tests a daily pill called filgotinib (200 mg) in about 94 Korean adults with moderate-to-severe ulcerative colitis. The main goal is to see if it can bring the disease into remission (quiet down symptoms) by week 10 or 22. Participants take the pill once a day and are …

This study tests whether adding the deworming drug mebendazole to standard mesalamine treatment can safely improve symptoms in people with mild-to-moderate ulcerative colitis. Researchers will measure changes in disease activity, blood markers, and symptom scores over time. The t…

This study tests an experimental drug called SAR442970 in 99 adults with moderate to severe ulcerative colitis. Participants receive either the drug or a placebo for 16 weeks, followed by a long-term extension where everyone can get the drug. The goal is to see if the drug can re…

This study follows about 80 Chinese adults with moderate to severe ulcerative colitis who are already prescribed upadacitinib by their doctor. Researchers will track how well the drug controls symptoms like bloody diarrhea over one year, using only routine checkup data. The goal …

This study looks at whether eating more fermented foods like yogurt, kimchi, and sauerkraut can reduce gut inflammation and improve daily life for people with mild to moderate ulcerative colitis. About 21 adults with the condition will add these foods to their diet for a period o…

This study tests whether adding the antihistamine desloratadine to standard treatment (mesalamine) can reduce inflammation and disease activity in people with mild to moderate ulcerative colitis. About 44 adults aged 18 to 65 who are already on mesalamine will take either deslora…

This study tests whether a five-day diet that tricks the body into a fasting state can reduce inflammation and improve quality of life in people with mild to moderate ulcerative colitis. Participants will follow the diet for three cycles while researchers track symptoms like stoo…

This study is testing whether robotic surgery is a safe and effective option for people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Researchers will compare robotic surgery to the standard laparoscopic approach, looking at things like …

This study follows 450 adults who have inflammatory bowel disease (IBD) but no symptoms yet. Researchers want to learn how the disease changes over time and what biological signs might predict future problems like pain, diarrhea, or complications. The goal is to better understand…

This study looks at whether changes in sleep can act as early warning signs for flare-ups in people with Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. Researchers will track sleep patterns and disease activity in 216 adults with IBD who are c…

This study collects tissue and blood samples from 300 people with autoimmune diseases like ulcerative colitis, multiple sclerosis, and Crohn's disease. Researchers will identify which T-cells are active in inflamed tissues and find their targets. The goal is to discover new targe…

This study is testing a new educational tool designed for people with melanoma who also have an autoimmune disease (like rheumatoid arthritis or Crohn's disease). The tool helps patients understand immune checkpoint inhibitor drugs and their possible side effects. Researchers wil…

This study looks at how pregnancy, childbirth, and breastfeeding affect inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Researchers will follow 945 women from a French registry to count disease flare-ups during and after pregnancy. The goal is …

This study is for adults in South Korea with ulcerative colitis or Crohn's disease who are already using vedolizumab injections. Researchers will look at medical records to see what side effects happen and how well the treatment works. No new medicine is given—it's just watching …

This study aims to learn how the immune system controls inflammation in the gut for people with Crohn's disease or ulcerative colitis. Researchers will observe up to 1,000 participants aged 0 to 75, using blood tests, tissue samples, and standard medical care. No experimental tre…

This study looks at how nutrition and body composition (like muscle mass) influence treatment results in people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Researchers will follow 300 patients starting new medical therapies or undergoi…

This study looks at how doctors around the world use a 'treat-to-target' approach for people with Crohn's disease or ulcerative colitis. Researchers will review medical records from 2,000 adults over 24 months to see if adjusting treatment based on regular check-ups leads to bett…

This study looks at whether ultrasound can detect scarring (fibrosis) in the gut of people with ulcerative colitis. Researchers will compare ultrasound images with tissue samples from colonoscopies to develop new, non-invasive ways to measure disease. The goal is to improve diagn…

This study tests whether nicotinamide riboside, a vitamin-like supplement, is safe and practical for children with mild to moderate ulcerative colitis. About 40 participants will take the supplement and be followed for up to 12 months. The main goal is to see if the study is feas…

This study looks at how having inflammatory bowel disease (Crohn's or colitis) as a child affects job and education in adulthood. Researchers will survey 460 adults diagnosed before age 17 to compare their work and school achievements with the general population. The goal is to u…

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…